The Cooper Cos. (NYSE:COO) – Research analysts at KeyCorp issued their FY2018 earnings per share estimates for shares of The Cooper Cos. in a report released on Thursday. KeyCorp analyst M. Mishan anticipates that the firm will post earnings of $11.06 per share for the year. KeyCorp currently has a “Buy” rating and a $221.00 target price on the stock.
COO has been the topic of a number of other reports. Stifel Nicolaus reiterated a “buy” rating and issued a $215.00 price objective on shares of The Cooper Cos. in a report on Friday, September 9th. Robert W. Baird reiterated an “outperform” rating and issued a $185.00 price objective on shares of The Cooper Cos. in a report on Saturday, June 25th. Zacks Investment Research downgraded shares of The Cooper Cos. from a “buy” rating to a “hold” rating in a report on Friday, August 5th. BMO Capital Markets lifted their price objective on shares of The Cooper Cos. from $199.00 to $206.00 and gave the company an “outperform” rating in a report on Friday, September 2nd. Finally, Jefferies Group lifted their price objective on shares of The Cooper Cos. from $190.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, August 24th. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $183.00.
Shares of The Cooper Cos. (NYSE:COO) opened at 179.26 on Monday. The company has a market capitalization of $8.74 billion, a P/E ratio of 35.10 and a beta of 0.29. The Cooper Cos. has a one year low of $119.28 and a one year high of $190.99. The firm has a 50-day moving average of $184.12 and a 200-day moving average of $169.26.
The Cooper Cos. (NYSE:COO) last issued its quarterly earnings results on Thursday, September 1st. The medical device company reported $2.30 earnings per share for the quarter, beating analysts’ consensus estimates of $2.29 by $0.01. The Cooper Cos. had a net margin of 13.14% and a return on equity of 14.89%. The firm earned $514.70 million during the quarter. During the same period last year, the company earned $1.97 earnings per share. The Cooper Cos.’s revenue for the quarter was up 11.5% on a year-over-year basis.
In other news, Director Michael Kalkstein sold 1,000 shares of the business’s stock in a transaction dated Friday, July 8th. The shares were sold at an average price of $178.55, for a total value of $178,550.00. Following the completion of the sale, the director now owns 14,215 shares of the company’s stock, valued at $2,538,088.25. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director William A. Kozy bought 270 shares of The Cooper Cos. stock in a transaction dated Tuesday, September 6th. The stock was acquired at an average cost of $186.69 per share, with a total value of $50,406.30. Following the transaction, the director now owns 770 shares of the company’s stock, valued at approximately $143,751.30. The disclosure for this purchase can be found here. 2.20% of the stock is currently owned by insiders.
Several large investors have recently made changes to their positions in the stock. BlueMountain Capital Management LLC acquired a new stake in shares of The Cooper Cos. during the first quarter worth about $113,000. Mizuho Asset Management Co. Ltd. boosted its stake in shares of The Cooper Cos. by 90.4% in the second quarter. Mizuho Asset Management Co. Ltd. now owns 672 shares of the medical device company’s stock worth $115,000 after buying an additional 319 shares during the last quarter. Robecosam AG acquired a new stake in shares of The Cooper Cos. during the second quarter worth about $136,000. Pacer Advisors Inc. boosted its stake in shares of The Cooper Cos. by 9.3% in the second quarter. Pacer Advisors Inc. now owns 821 shares of the medical device company’s stock worth $141,000 after buying an additional 70 shares during the last quarter. Finally, Chilton Capital Management LLC acquired a new stake in shares of The Cooper Cos. during the first quarter worth about $203,000. 98.67% of the stock is owned by institutional investors.
About The Cooper Cos.
The Cooper Companies, Inc (Cooper) is a medical device company. The Company operates through two business units: CooperVision, Inc (CooperVision) and CooperSurgical, Inc (CooperSurgical). CooperVision develops, manufactures and markets a range of soft contact lenses for the vision correction market. CooperVision offers Biofinity monthly spherical, toric and multifocal lenses under the Avaira brand.
Receive News & Ratings for The Cooper Cos. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Cooper Cos. and related companies with MarketBeat.com's FREE daily email newsletter.